Drug Type mRNA encoding bispecific antibody, Bispecific T-cell Engager (BiTE) |
Synonyms ABO 2203, ABO2203 |
Target |
Action modulators |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD3 modulators(T cell surface glycoprotein CD3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Phase 1 | China | 24 Dec 2024 | |
Idiopathic Inflammatory Myopathies | Phase 1 | China | 01 Dec 2024 | |
Lupus Nephritis | Phase 1 | China | 01 Dec 2024 | |
Rheumatoid Arthritis | Phase 1 | China | 01 Dec 2024 | |
Scleroderma, Systemic | Phase 1 | China | 01 Dec 2024 |